Zydus Lifesciences gets USFDA observations for Moraiya facilityZYDUSLIFE - 643 Change: 5.65 (0.89 %)
News: USFDA concluded an inspection of Zydus lifesciences, moraiya manufacturing facility from 26th July to 5th August, 2022 with four Form 483 observations. None of the observations were related to data integrity. Company will address the observations within the stipulated timeline.
View: Moraiya manufacturing facility is earmarked for Oral Solids, Injections, Nasals, Aerosols and Transdermals. However, Transdermals hold a much bigger significance for Zydus as majority of high value products excluding transdermals have now been site transferred to alternate facilities. Transdermals is a more sticky business and clearance for Moraiya facility remains an important step for new launches in US.